Anna Berglind

2.2k total citations · 3 hit papers
12 papers, 1.4k citations indexed

About

Anna Berglind is a scholar working on Rheumatology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anna Berglind has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anna Berglind's work include Systemic Lupus Erythematosus Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Anna Berglind is often cited by papers focused on Systemic Lupus Erythematosus Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Anna Berglind collaborates with scholars based in Sweden, United States and United Kingdom. Anna Berglind's co-authors include Raj Tummala, Eric F. Morand, Philip Z. Brohawn, Ian N Bruce, Richard Furie, Yoshiya Tanaka, Christophe Richez, Sang‐Cheol Bae, Anca Askanase and Lilia Pineda and has published in prestigious journals such as New England Journal of Medicine, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

Anna Berglind

12 papers receiving 1.4k citations

Hit Papers

Trial of Anifrolumab in Active Systemic Lupus Erythematosus 2019 2026 2021 2023 2019 2019 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
    2019 778 citations Eric F. Morand, Richard Furie et al. New England Journal of Medicine profile →
  2. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
    2019 289 citations Richard Furie, Eric F. Morand et al. The Lancet Rheumatology profile →
  3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
    2023 158 citations Eric A. F. Simões, Shabir A. Madhi et al. The Lancet Child & Adolescent Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Berglind Sweden 9 983 756 427 227 223 12 1.4k
Omid Zamani United States 6 1.5k 1.5× 1.3k 1.7× 641 1.5× 260 1.1× 195 0.9× 12 2.1k
Dana Tegzová Czechia 15 1.7k 1.7× 1.0k 1.3× 657 1.5× 250 1.1× 95 0.4× 22 2.1k
Juan Carlos Mejía United States 10 909 0.9× 514 0.7× 189 0.4× 152 0.7× 118 0.5× 27 1.3k
Beulah Ji United States 14 1.3k 1.3× 880 1.2× 619 1.4× 108 0.5× 102 0.5× 31 1.6k
Juanita Romero‐Díaz Mexico 17 1.0k 1.0× 639 0.8× 272 0.6× 119 0.5× 70 0.3× 50 1.3k
Paula Alba Argentina 9 1.2k 1.3× 672 0.9× 273 0.6× 55 0.2× 134 0.6× 34 1.4k
Cecile Grootscholten Netherlands 21 563 0.6× 362 0.5× 153 0.4× 348 1.5× 167 0.7× 52 1.4k
José Ramón Maneiro Spain 15 741 0.8× 347 0.5× 126 0.3× 92 0.4× 88 0.4× 28 1.1k
Massimo Radin Italy 21 941 1.0× 327 0.4× 133 0.3× 41 0.2× 98 0.4× 112 1.3k
Neil Solomons United States 11 1.9k 1.9× 646 0.9× 373 0.9× 82 0.4× 144 0.6× 23 2.1k

Countries citing papers authored by Anna Berglind

Since Specialization
Citations

This map shows the geographic impact of Anna Berglind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Berglind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Berglind more than expected).

Fields of papers citing papers by Anna Berglind

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Berglind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Berglind. The network helps show where Anna Berglind may publish in the future.

Co-authorship network of co-authors of Anna Berglind

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Berglind. A scholar is included among the top collaborators of Anna Berglind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Berglind. Anna Berglind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Simões, Eric A. F., Shabir A. Madhi, William J. Muller, et al.. (2023). Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. The Lancet Child & Adolescent Health. 7(3). 180–189. 158 indexed citations breakdown →
2.
McMenamin, Martina, Michael J. Grayling, Anna Berglind, & James Wason. (2021). Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. BMC Rheumatology. 5(1). 54–54. 1 indexed citations
3.
McMenamin, Martina, Jessica Barrett, Anna Berglind, & James Wason. (2020). Employing a latent variable framework to improve efficiency in composite endpoint analysis. Statistical Methods in Medical Research. 30(3). 702–716. 6 indexed citations
4.
Hammond, Edward R., Raj Tummala, Anna Berglind, et al.. (2020). Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature. BMJ Open. 10(9). e036563–e036563. 8 indexed citations
5.
Keene, Oliver N., Stephen J. Ruberg, Alexander Schacht, et al.. (2020). What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. Pharmaceutical Statistics. 19(4). 370–387. 15 indexed citations
6.
Furie, Richard, Eric F. Morand, Ian N Bruce, et al.. (2019). Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. The Lancet Rheumatology. 1(4). e208–e219. 289 indexed citations breakdown →
7.
Morand, Eric F., Richard Furie, Yoshiya Tanaka, et al.. (2019). Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine. 382(3). 211–221. 778 indexed citations breakdown →
8.
McMenamin, Martina, Anna Berglind, & James Wason. (2018). Improving the analysis of composite endpoints in rare disease trials. Orphanet Journal of Rare Diseases. 13(1). 81–81. 9 indexed citations
9.
10.
Tummala, Raj, et al.. (2018). Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Science & Medicine. 5(1). e000252–e000252. 23 indexed citations
11.
12.
Sims, Karen, Julie A. Lemm, Timothy Eley, et al.. (2014). Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection. Antimicrobial Agents and Chemotherapy. 58(6). 3496–3503. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Omid Zamani Breakdown of academic impact, for papers by Dana Tegzová Breakdown of academic impact, for papers by Juan Carlos Mejía Breakdown of academic impact, for papers by Beulah Ji Breakdown of academic impact, for papers by Juanita Romero‐Díaz Breakdown of academic impact, for papers by Paula Alba Breakdown of academic impact, for papers by Cecile Grootscholten Breakdown of academic impact, for papers by José Ramón Maneiro Breakdown of academic impact, for papers by Massimo Radin Breakdown of academic impact, for papers by Neil Solomons
Rankless by CCL
2026